A share price of Immuneering Corp [IMRX] is currently trading at $3.53, up 10.66%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IMRX shares have gain 37.89% over the last week, with a monthly amount glided 96.11%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Immuneering Corp [NASDAQ: IMRX] stock has seen the most recent analyst activity on December 13, 2024, when Morgan Stanley downgraded its rating to a Underweight. Previously, Needham reaffirmed its Buy rating on March 15, 2024, and dropped its price target to $15. On March 15, 2024, downgrade downgraded it’s rating to Market Perform. Jefferies downgraded its rating to a Hold and decreased its price target to $3 on March 15, 2024. Needham initiated its recommendation with a Buy and recommended $20 as its price target on December 01, 2023. In a note dated April 19, 2023, Morgan Stanley upgraded an Equal-Weight rating on this stock and boosted its target price from $5 to $14.
Immuneering Corp experienced fluctuations in its stock price throughout the past year between $1.00 and $3.83. Currently, Wall Street analysts expect the stock to reach $17.5 within the next 12 months. Immuneering Corp [NASDAQ: IMRX] shares were valued at $3.53 at the most recent close of the market. An investor can expect a potential return of 395.75% based on the average IMRX price forecast.
Analyzing the IMRX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.22, Equity is -1.19 and Total Capital is -1.41. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.16 points at the first support level, and at 2.78 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.89, and for the 2nd resistance point, it is at 4.25.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Immuneering Corp [NASDAQ:IMRX] is 7.48. In addition, the Quick Ratio stands at 7.48 and the Cash Ratio stands at 7.02.
Transactions by insiders
Recent insider trading involved Hall Brett Matthew, CHIEF SCIENTIFIC OFFICER, that happened on Jun 20 ’25 when 7415.0 shares were purchased. CHIEF SCIENTIFIC OFFICER, Hall Brett Matthew completed a deal on Jun 23 ’25 to buy 6007.0 shares. Meanwhile, Chief Business Officer Brakewood Harold Eugene bought 1900.0 shares on Jun 20 ’25.
